Subtle Trap for the Inflammatory Bowel Disease Endoscopy Central Reader

Abstract

Question: A 75-year-old female patient with refractory Crohn’s disease underwent an endoscopy to assess the endoscopic disease activity during an open label extension of a clinical trial with an new IL-23 antagonist (risankizumab). She was known with a long standing Crohn’s disease (Montreal classification A2L3B2) for >45 years, requiring prior ileocecal resection and partial colectomy. Endoscopy prior to the start of the treatment in April 2018 showed severe disease activity (Simple Endoscopic Score for Crohn’s Disease of 14) with an inflammatory stenosis with deep ulcerations in the proximal rectum.